<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Einstein (Sao Paulo)</journal-id><journal-id journal-id-type="iso-abbrev">Einstein (Sao Paulo)</journal-id><journal-id journal-id-type="publisher-id">eins</journal-id><journal-title-group><journal-title>Einstein</journal-title></journal-title-group><issn pub-type="ppub">1679-4508</issn><issn pub-type="epub">2317-6385</issn><publisher><publisher-name>Instituto Israelita de Ensino e Pesquisa Albert Einstein</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40367007</article-id><article-id pub-id-type="pmc">PMC12094673</article-id>
<article-id pub-id-type="other">00225</article-id><article-id pub-id-type="doi">10.31744/einstein_journal/2025AO1124</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Omission of dexamethasone in prophylaxis for highly emetogenic chemotherapy in patients with breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7333-398X</contrib-id><name><surname>de Rebou&#x000e7;as</surname><given-names>Camilla Vieira</given-names></name><role>contributed to the concept and design of the article and the interpretation of data</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5416-1163</contrib-id><name><surname>Alves</surname><given-names>Rafaela de Brito</given-names></name><role>contributed to data acquisition and analysis</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9778-6123</contrib-id><name><surname>Yamada</surname><given-names>Alayne Magalh&#x000e3;es Trindade Domingues</given-names></name><role>contributed to the concept and design of the study</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2009-824X</contrib-id><name><surname>del Giglio</surname><given-names>Auro</given-names></name><role>contributed to the interpretation of data</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4558-4850</contrib-id><name><surname>Cruz</surname><given-names>Felipe Jos&#x000e9; Silva Melo</given-names></name><role>contributed to the concept and design of the article and the interpretation of data</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="orgname">N&#x000fa;cleo de Pesquisa e Ensino IBCC Oncologia</institution>
<addr-line>
<named-content content-type="city">S&#x000e3;o Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">N&#x000fa;cleo de Pesquisa e Ensino IBCC Oncologia, S&#x000e3;o Paulo, SP, Brazil.</institution>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="orgname">Centro Universit&#x000e1;rio FMABC</institution>
<addr-line>
<named-content content-type="city">S&#x000e3;o Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brazil</country>
<institution content-type="original">Centro Universit&#x000e1;rio FMABC, S&#x000e3;o Paulo, SP, Brazil.</institution>
</aff><author-notes><corresp id="c01">
<label>Corresponding author</label>: Camilla Vieira de Rebou&#x000e7;as Avenida Conselheiro Rodrigues Alves, 820 - Vila Mariana Zip code: 04014-002 - S&#x000e3;o Paulo, SP, Brazil Phone: (55 11) 3474-4249 E-mail: <email>cdereboucas@gmail.com</email>
</corresp><fn fn-type="edited-by"><p><bold>Associate Editor:</bold> Maria Carolina Santos Mendes Faculdade de Ci&#x000ea;ncias M&#x000e9;dicas, Universidade Estadual de Campinas, Campinas, SP, Brazil ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-2442-1956" ext-link-type="uri">https://orcid.org/0000-0002-2442-1956</ext-link>
</p></fn><fn fn-type="COI-statement"><p><bold>Conflict of interest:</bold> none.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>eAO1124</elocation-id><history><date date-type="received"><day>21</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p></license></permissions><abstract><title>ABSTRACT</title><sec><title>Objective</title><p> Chemotherapy-induced nausea and vomiting are highly prevalent adverse events that can lead to poor treatment adherence and a decreased quality of life. To the best of our knowledge, the complete omission of dexamethasone from any regimen for preventing nausea and vomiting has not yet been evaluated. This study aimed to evaluate the efficacy of a three-drug protocol without corticosteroids for preventing nausea and vomiting.</p></sec><sec><title>Methods</title><p> This prospective, single-arm, phase II study was designed to evaluate the efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting induced by emetogenic chemotherapy. Patients were assigned to receive olanzapine on days 1-5 and netupitant and palonosetron on day 1. No corticosteroids were administered. The primary endpoint was complete nausea control during the first 5 days after chemotherapy. Secondary endpoints included complete emesis control (no emesis and no use of rescue medication) and overall complete control (no emesis, no rescue medication, and no nausea).</p></sec><sec><title>Results</title><p> The complete nausea control rate was 46% (95% confidence interval [95%CI] 0.32-0.59). The emesis control rate was 68% (95%CI= 0.55-0.80), and the overall control rate was 46% (95%CI= 0.32-0.59).</p></sec><sec><title>Conclusion</title><p> These findings suggest that omitting dexamethasone in highly emetogenic chemotherapy is feasible and results in nausea and vomiting control rates similar to those of the standard four-drug protocol. However, randomized controlled trials are required to confirm this hypothesis.</p></sec></abstract><abstract abstract-type="graphical"><p>
<fig position="float" id="f01"><graphic xlink:href="2317-6385-eins-23-eAO1124-gf01" position="float"/></fig>
</p></abstract><abstract abstract-type="summary"><title>In Brief</title><p> A phase II study evaluated a corticosteroid-free regimen (olanzapine, netupitant, and palonosetron) for the treatment of chemotherapy-induced nausea and vomiting. The results showed control rates comparable to those of standard protocols, demonstrating its feasibility without dexamethasone.</p></abstract><abstract abstract-type="key-points"><title>Highlights</title><p>&#x025a0; Evaluation of a corticosteroid-free antiemetic regimen.</p><p>&#x025a0; Primary endpoint: 46% nausea control.</p><p>&#x025a0; Secondary endpoint: 68% emesis control.</p><p>&#x025a0; Comparable to standard four-drug protocols.</p></abstract><kwd-group><kwd>Dexamethasone</kwd><kwd>Drug therapy</kwd><kwd>Nausea</kwd><kwd>Olanzapine</kwd><kwd>Vomiting</kwd><kwd>Breast neoplasms</kwd><kwd>Antineoplastic agents</kwd><kwd>Drug-related side effects and adverse reactions</kwd></kwd-group><counts><fig-count count="2"/><table-count count="3"/><equation-count count="0"/><ref-count count="31"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Chemotherapy-induced nausea and vomiting are highly prevalent adverse events<sup><xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref></sup> that can lead to a decreased quality of life, dose reductions, and treatment interruptions.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> Treatment protocols are classified as highly, moderately, or low emetogenic chemotherapy.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> Combination of anthracycline and cyclophosphamide (AC) has been the backbone of treatment of different breast cancer scenarios and, in many cases, remains the standard of care.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Anthracycline and cyclophosphamide is associated with an up to 83% risk of nausea and vomiting and is therefore considered highly emetogenic.<sup><xref rid="B7" ref-type="bibr">7</xref>-<xref rid="B9" ref-type="bibr">9</xref></sup></p><p>The current standard of care for highly emetogenic chemotherapy (HEC) is a four-drug regimen consisting of olanzapine,<sup><xref rid="B10" ref-type="bibr">10</xref></sup> a 5-hydroxytryptamine type 3 receptor (5HT3) antagonist, a neurokinin 1 receptor (NK1) antagonist, and dexamethasone.<sup><xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B11" ref-type="bibr">11</xref>-<xref rid="B13" ref-type="bibr">13</xref></sup> This highly effective protocol can achieve up to 60% complete control of emesis.<sup><xref rid="B10" ref-type="bibr">10</xref></sup></p><p>The first NK1 antagonist (aprepitant) was approved in 2004.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Until then, the recommended scheme for nausea prevention consisted of dexamethasone plus a 5HT3 antagonist (ondansetron or palonosetron),<sup><xref rid="B14" ref-type="bibr">14</xref></sup> with or without the dopamine antagonist metoclopramide.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> In 2014, a fixed-dose oral combination of netupitant and palonosetron, combined with dexamethasone, was approved for preventing chemotherapy-associated nausea and vomiting.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> Olanzapine was added to the 2017 guidelines for HEC<sup><xref rid="B16" ref-type="bibr">16</xref></sup> after a positive phase III trial was published in 2016.<sup><xref rid="B10" ref-type="bibr">10</xref></sup></p><p>Corticosteroids have been used for decades to prevent nausea associated with chemotherapy and radiotherapy.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Their antiemetic effects are attributed to the reduced production of inflammatory mediators, such as eicosanoids, inhibiting serotonin production, and modulating the hypothalamic-pituitary-adrenal axis.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> However, corticosteroids also affect lipid and glucose metabolism, bone maintenance, immune system regulation, memory, mood, and sleep balance. Therefore, they are associated with side effects such as insomnia, weight gain, and mood disorders.<sup><xref rid="B18" ref-type="bibr">18</xref>-<xref rid="B20" ref-type="bibr">20</xref></sup></p><p>Avoiding dexamethasone may also benefit patients receiving concurrent immunotherapy, as steroids have the potential to reduce immunotherapy effectiveness.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> To our knowledge, the complete omission of dexamethasone from nausea prevention protocols for HEC has not been evaluated previously.<sup><xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B22" ref-type="bibr">22</xref></sup></p></sec><sec><title>OBJECTIVE</title><p>This study aimed to evaluate the efficacy of a three-drug protocol without corticosteroids for preventing nausea and vomiting.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This prospective, single-arm, phase II study was designed to evaluate the efficacy of olanzapine, netupitant, and palonosetron in controlling HEC-induced nausea and vomiting. The trial was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of <italic toggle="yes">Instituto Brasileiro de Controle do Cancer</italic> (CAAE: 38285020.8.0000.0072; #4.483.028). Eligible patients were women with histologically confirmed breast cancer who were scheduled to start treatment with doxorubicin and cyclophosphamide. Exclusion criteria included the use of opioids or antipsychotic medications, the presence of medical conditions that could potentially cause vomiting, and the inability to take oral medications. Informed consent was obtained from all participants. Patients were assigned to receive olanzapine (5mg once daily) on days 1-5 and netupitant (300mg) with palonosetron (0.5mg) on day 1. No corticosteroids were administered. Outcomes were analyzed using the classic visual analog scale,<sup><xref rid="B23" ref-type="bibr">23</xref></sup> which was completed by the patients during the first 5 days of treatment. Additionally, a questionnaire was used to collect sociodemographic information.</p><p>The primary endpoint was complete control of nausea during the first 5 days after chemotherapy administration. Secondary endpoints included complete emesis control (no emesis and no use of rescue medication for the first 120h), complete control (no emesis, no nausea, and no rescue medication for the first 120h), and rates of acute and delayed nausea. Acute nausea was defined as nausea occurring within the first 24h after treatment, whereas delayed nausea referred to nausea occurring within the first 5 days after chemotherapy.</p><sec><title>Statistical analysis</title><p>Summary statistics are presented as frequencies and proportions for categorical data and as means and ranges for continuous variables.</p><p>The null hypothesis considered that a regimen containing olanzapine, netupitant, and palonosetron would not effectively control nausea. Based on a previous phase III study of olanzapine,<sup><xref rid="B24" ref-type="bibr">24</xref></sup> we set a nausea control rate of 20% and expected control rate of 40% for the present study. To achieve a 5% significance level (two-sided) and 80% statistical power, we calculated a minimum sample size of 50 patients, assuming a 5% dropout rate. A one-sample test of proportion was used to analyze the data based on a per-protocol analysis.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Of 59 patients eligible for participation in the study, we excluded 5 patients who withdrew consent and 4 who took corticosteroids against the recommendation. Therefore, 50 patients were enrolled between January 2020 and December 2021 (<xref rid="f02" ref-type="fig">Figure 1</xref>).</p><p>
<fig position="float" id="f02"><label>Figure 1</label><caption><title>Study selection of participants</title></caption><graphic xlink:href="2317-6385-eins-23-eAO1124-gf02" position="float"/></fig>
</p><p>The mean age of the study population was 47.6 years (range, 29-78 years). A minority of patients (4%) received chemotherapy with palliative intent, whereas 96% received chemotherapy with curative intent. Ten patients (20%) reported a history of smoking, and only one patient (2%) reported a history of alcohol abuse. A summary of the baseline characteristics is presented in <xref rid="t1" ref-type="table">table 1</xref>.</p><p>
<table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Demographic and clinical characteristics of the study patients</title></caption><table frame="hsides" rules="groups"><colgroup width="50%" span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">Age, year</th><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">47.6</td></tr><tr><td rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">29-78</td></tr><tr><td rowspan="1" colspan="1">Race, n (%)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">White</td><td align="center" rowspan="1" colspan="1">26 (52)</td></tr><tr><td rowspan="1" colspan="1">Black</td><td align="center" rowspan="1" colspan="1">21 (42)</td></tr><tr><td rowspan="1" colspan="1">Asian</td><td align="center" rowspan="1" colspan="1">2 (4)</td></tr><tr><td rowspan="1" colspan="1">Hispanic</td><td align="center" rowspan="1" colspan="1">1 (2)</td></tr><tr><td rowspan="1" colspan="1">Education level, n (%)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">No formal education</td><td align="center" rowspan="1" colspan="1">2 (4)</td></tr><tr><td rowspan="1" colspan="1">Elementary school</td><td align="center" rowspan="1" colspan="1">7 (14)</td></tr><tr><td rowspan="1" colspan="1">Intermediate school</td><td align="center" rowspan="1" colspan="1">12 (24)</td></tr><tr><td rowspan="1" colspan="1">High school</td><td align="center" rowspan="1" colspan="1">16 (32)</td></tr><tr><td rowspan="1" colspan="1">Graduate school</td><td align="center" rowspan="1" colspan="1">11 (22)</td></tr><tr><td rowspan="1" colspan="1">Postgraduate</td><td align="center" rowspan="1" colspan="1">2 (4)</td></tr><tr><td rowspan="1" colspan="1">Chemotherapy intent, n (%)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Curative</td><td align="center" rowspan="1" colspan="1">48 (96)</td></tr><tr><td rowspan="1" colspan="1">Palliative</td><td align="center" rowspan="1" colspan="1">2 (4)</td></tr><tr><td rowspan="1" colspan="1">Smoking History, n (%)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">40 (80)</td></tr><tr><td rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">10 (20)</td></tr><tr><td rowspan="1" colspan="1">Alcohol Abuse History, n (%)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">49 (98)</td></tr><tr><td rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">1 (2)</td></tr></tbody></table></table-wrap>
</p><p>For the primary endpoint, the complete nausea control rate was 46% (95%CI= 0.32-0.59). The acute and delayed nausea control rates were both 52% (95%CI= 0.38-0.65; <xref rid="t2" ref-type="table">Table 2</xref>). For the secondary endpoints, the emesis control rate was 68% (95%CI= 0.55-0.80), and the complete control rate was 46% (95%CI= 0.32-0.59) (<xref rid="t3" ref-type="table">Table 3</xref>). One patient dropped out due to grade 2 dizziness and drowsiness following the administration of olanzapine but was included in the final analysis.</p><p>
<table-wrap position="float" id="t2"><label>Table 2</label><caption><title>Nausea control rate</title></caption><table frame="hsides" rules="groups"><colgroup width="33%" span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Total</th><th rowspan="1" colspan="1">95%CI</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">0-24h after chemotherapy (acute), n (%)</td></tr><tr><td rowspan="1" colspan="1">No nausea</td><td align="center" rowspan="1" colspan="1">26 (52)</td><td align="center" rowspan="1" colspan="1">0.38-0.65</td></tr><tr><td rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">24 (48)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="3" rowspan="1">24-120h after chemotherapy (delayed), n (%)</td></tr><tr><td rowspan="1" colspan="1">No nausea</td><td align="center" rowspan="1" colspan="1">26 (52)</td><td align="center" rowspan="1" colspan="1">0.38-0.65</td></tr><tr><td rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">24 (48)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="3" rowspan="1">0-120h after chemotherapy (overall), n (%)</td></tr><tr><td rowspan="1" colspan="1">No nausea</td><td align="center" rowspan="1" colspan="1">23 (46)</td><td align="center" rowspan="1" colspan="1">0.32-0.59</td></tr><tr><td rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">27 (54)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap>
</p><p>
<table-wrap position="float" id="t3"><label>Table 3</label><caption><title>Emesis, overall nausea, and vomiting control</title></caption><table frame="hsides" rules="groups"><colgroup width="33%" span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Total</th><th rowspan="1" colspan="1">95%CI</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">Emesis control 0-120 h after chemotherapy, n (%)</td></tr><tr><td rowspan="1" colspan="1">No emesis</td><td align="center" rowspan="1" colspan="1">34 (68)</td><td align="center" rowspan="1" colspan="1">0.55-0.80</td></tr><tr><td rowspan="1" colspan="1">Emesis</td><td align="center" rowspan="1" colspan="1">16 (32)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="3" rowspan="1">Overall nausea and vomiting control rate, n (%)</td></tr><tr><td rowspan="1" colspan="1">No nausea/no emesis</td><td align="center" rowspan="1" colspan="1">23 (46)</td><td align="center" rowspan="1" colspan="1">0.32-0.59</td></tr><tr><td rowspan="1" colspan="1">Nausea/emesis</td><td align="center" rowspan="1" colspan="1">27 (54)</td><td rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This trial provides a new perspective on nausea and vomiting prevention as to our knowledge, no trial has attempted to exclude corticosteroids from protocols for preventing chemotherapy-induced nausea and vomiting.<sup><xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B25" ref-type="bibr">25</xref></sup> This approach is particularly interesting for patients with specific or relative contraindications to corticosteroid use, such as diabetes, a history of gastric ulcer, osteoporosis, tuberculosis, and glaucoma. Moreover, excluding corticosteroids could minimize weight gain, insomnia, immunosuppression, and edema.<sup><xref rid="B25" ref-type="bibr">25</xref>,<xref rid="B26" ref-type="bibr">26</xref></sup> A phase II trial assessed the adverse effects of dexamethasone use in chemotherapy-induced nausea and vomiting prophylaxis and found that insomnia was the most frequent adverse event, followed by gastric discomfort.<sup><xref rid="B26" ref-type="bibr">26</xref></sup> Owing to the high rate of reported symptoms, a controlled trial was suggested to evaluate the feasibility of a non-steroid protocol for preventing chemotherapy-induced nausea and vomiting.</p><p>We propose a protocol for controlling chemotherapy-induced nausea and vomiting that completely omits corticosteroids. One non-inferiority trial evaluated a dexamethasone-sparing regimen, comparing 12mg of dexamethasone administered only on day 1 to 12mg administered on days 1-4. The protocol also included netupitant and palonosetron but did not include olanzapine. The non-inferiority endpoint was satisfied.<sup><xref rid="B27" ref-type="bibr">27</xref></sup> The no-steroid protocol proposed in this study-which used olanzapine, netupitant, and palonosetron-achieved an overall nausea control rate of 46%. This finding is similar to that reported by Navari et al.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> in a study that described and validated a four-drug regimen, which has become the gold standard in the prevention of chemotherapy-induced nausea and vomiting. Similar studies involving olanzapine have also demonstrated its efficacy.<sup><xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B28" ref-type="bibr">28</xref></sup> A published meta-analysis concluded that adding olanzapine could reduce the incidence of nausea from 75% to 50% in chemotherapy-induced nausea and vomiting.<sup><xref rid="B29" ref-type="bibr">29</xref></sup></p><p>We chose to use olanzapine at a 5 mg daily dose, half the dose used in the trial described by Navari et al.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> This dose reduction has already been proposed and validated by guidelines and previous studies to prevent sedation caused by the drug.<sup><xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B30" ref-type="bibr">30</xref></sup> Nevertheless, one dropout due to drowsiness and sleepiness occurred in our study. A trial published in 2024 evaluated lower doses of olanzapine (2.5mg) for emesis prophylaxis and achieved a non-inferior endpoint.<sup><xref rid="B31" ref-type="bibr">31</xref></sup></p><p>One limitation of this study is that we included only patients with breast cancer receiving doxorubicin and cyclophosphamide, limiting the generalizability of our findings to patients with other cancers or those receiving different chemotherapy regimens. A randomized controlled phase III trial, including a broader population, is necessary to validate the complete omission of corticosteroids in preventing chemotherapy-induced nausea and vomiting.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Omitting dexamethasone for highly emetogenic chemotherapy is feasible and shows similar control of nausea and vomiting to that of the standard four-drug protocol. Further phase III controlled studies are needed to validate this protocol as a potential prophylactic regimen of choice for patients with contraindications for dexamethasone use.</p></sec><sec><title>STATEMENTS AND DECLARATIONS</title><p>Felipe Jos&#x000e9; Silva Melo Cruz has served on advisory boards for Novartis and Janssen and has received travel support from Janssen.</p></sec></body><back><fn-group><fn fn-type="other"><p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04669132" ext-link-type="uri">NCT04669132</ext-link>.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segawa</surname><given-names>Y</given-names></name>
<name><surname>Aogi</surname><given-names>K</given-names></name>
<name><surname>Inoue</surname><given-names>K</given-names></name>
<name><surname>Sano</surname><given-names>M</given-names></name>
<name><surname>Sekine</surname><given-names>I</given-names></name>
<name><surname>Tokuda</surname><given-names>Y</given-names></name>
<name><surname>Isobe</surname><given-names>H</given-names></name>
<name><surname>Ogura</surname><given-names>T</given-names></name>
<name><surname>Tsuboi</surname><given-names>M</given-names></name>
<name><surname>Atagi</surname><given-names>S</given-names></name>
<collab>PALO Japanese Cooperative Study Group</collab>
</person-group><article-title>A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><issue>11</issue><fpage>1874</fpage><lpage>1880</lpage><pub-id pub-id-type="pmid">19605507</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razvi</surname><given-names>Y</given-names></name>
<name><surname>Chan</surname><given-names>S</given-names></name>
<name><surname>McFarlane</surname><given-names>T</given-names></name>
<name><surname>McKenzie</surname><given-names>E</given-names></name>
<name><surname>Zaki</surname><given-names>P</given-names></name>
<name><surname>DeAngelis</surname><given-names>C</given-names></name>
<etal>et al</etal>
</person-group><article-title>ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients</article-title><source>Support Care Cancer</source><year>2019</year><volume>27</volume><issue>1</issue><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">30284039</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cruz</surname><given-names>FM</given-names></name>
<name><surname>de Iracema Gomes Cubero</surname><given-names>D</given-names></name>
<name><surname>Taranto</surname><given-names>P</given-names></name>
<name><surname>Lerner</surname><given-names>T</given-names></name>
<name><surname>Lera</surname><given-names>AT</given-names></name>
<name><surname>da Costa Miranda</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study</article-title><source>Support Care Cancer</source><year>2012</year><volume>20</volume><issue>3</issue><fpage>601</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">21465325</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hesketh</surname><given-names>PJ</given-names></name>
</person-group><article-title>Chemotherapy-induced nausea and vomiting</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>23</issue><fpage>2482</fpage><lpage>2494</lpage><pub-id pub-id-type="pmid">18525044</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okada</surname><given-names>Y</given-names></name>
<name><surname>Oba</surname><given-names>K</given-names></name>
<name><surname>Furukawa</surname><given-names>N</given-names></name>
<name><surname>Kosaka</surname><given-names>Y</given-names></name>
<name><surname>Okita</surname><given-names>K</given-names></name>
<name><surname>Yuki</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis</article-title><source>Oncologist</source><year>2019</year><volume>24</volume><issue>12</issue><fpage>1593</fpage><lpage>1600</lpage><pub-id pub-id-type="pmid">31217343</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fisusi</surname><given-names>FA</given-names></name>
<name><surname>Akala</surname><given-names>EO</given-names></name>
</person-group><article-title>Drug Combinations in Breast Cancer Therapy</article-title><source>Pharm Nanotechnol</source><year>2019</year><volume>7</volume><issue>1</issue><fpage>3</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">30666921</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hesketh</surname><given-names>PJ</given-names></name>
<name><surname>Kris</surname><given-names>MG</given-names></name>
<name><surname>Grunberg</surname><given-names>SM</given-names></name>
<name><surname>Beck</surname><given-names>T</given-names></name>
<name><surname>Hainsworth</surname><given-names>JD</given-names></name>
<name><surname>Harker</surname><given-names>G</given-names></name>
<etal>et al</etal>
</person-group><article-title>Proposal for classifying the acute emetogenicity of cancer chemotherapy</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><issue>1</issue><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">8996130</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grunberg</surname><given-names>SM</given-names></name>
<name><surname>Warr</surname><given-names>D</given-names></name>
<name><surname>Gralla</surname><given-names>RJ</given-names></name>
<name><surname>Rapoport</surname><given-names>BL</given-names></name>
<name><surname>Hesketh</surname><given-names>PJ</given-names></name>
<name><surname>Jordan</surname><given-names>K</given-names></name>
<etal>et al</etal>
</person-group><article-title>Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art</article-title><source>Support Care Cancer</source><year>2011</year><volume>19</volume><issue>S1</issue><supplement>Suppl 1</supplement><fpage>S43</fpage><lpage>S47</lpage><pub-id pub-id-type="pmid">20972805</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Navari</surname><given-names>RM</given-names></name>
<name><surname>Aapro</surname><given-names>M</given-names></name>
</person-group><article-title>Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><issue>14</issue><fpage>1356</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">27050207</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Navari</surname><given-names>RM</given-names></name>
<name><surname>Qin</surname><given-names>R</given-names></name>
<name><surname>Ruddy</surname><given-names>KJ</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
<name><surname>Powell</surname><given-names>SF</given-names></name>
<name><surname>Bajaj</surname><given-names>M</given-names></name>
<etal>et al</etal>
</person-group><article-title>Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>2</issue><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">27410922</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roila</surname><given-names>F</given-names></name>
<name><surname>Molassiotis</surname><given-names>A</given-names></name>
<name><surname>Herrstedt</surname><given-names>J</given-names></name>
<name><surname>Aapro</surname><given-names>M</given-names></name>
<name><surname>Gralla</surname><given-names>RJ</given-names></name>
<name><surname>Bruera</surname><given-names>E</given-names></name>
<name><surname>Clark-Snow</surname><given-names>RA</given-names></name>
<name><surname>Dupuis</surname><given-names>LL</given-names></name>
<name><surname>Einhorn</surname><given-names>LH</given-names></name>
<name><surname>Feyer</surname><given-names>P</given-names></name>
<name><surname>Hesketh</surname><given-names>PJ</given-names></name>
<name><surname>Jordan</surname><given-names>K</given-names></name>
<name><surname>Olver</surname><given-names>I</given-names></name>
<name><surname>Rapoport</surname><given-names>BL</given-names></name>
<name><surname>Roscoe</surname><given-names>J</given-names></name>
<name><surname>Ruhlmann</surname><given-names>CH</given-names></name>
<name><surname>Walsh</surname><given-names>D</given-names></name>
<name><surname>Warr</surname><given-names>D</given-names></name>
<name><surname>van der Wetering</surname><given-names>M</given-names></name>
<collab>participants of the MASCC/ESMO Consensus Conference Copenhagen 2015</collab>
</person-group><article-title>2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><issue>suppl 5</issue><fpage>v119</fpage><lpage>v133</lpage><pub-id pub-id-type="pmid">27664248</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hashimoto</surname><given-names>H</given-names></name>
<name><surname>Abe</surname><given-names>M</given-names></name>
<name><surname>Tokuyama</surname><given-names>O</given-names></name>
<name><surname>Mizutani</surname><given-names>H</given-names></name>
<name><surname>Uchitomi</surname><given-names>Y</given-names></name>
<name><surname>Yamaguchi</surname><given-names>T</given-names></name>
<etal>et al</etal>
</person-group><article-title>Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Oncol</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>242</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">31838011</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakashima</surname><given-names>K</given-names></name>
<name><surname>Murakami</surname><given-names>H</given-names></name>
<name><surname>Yokoyama</surname><given-names>K</given-names></name>
<name><surname>Omori</surname><given-names>S</given-names></name>
<name><surname>Wakuda</surname><given-names>K</given-names></name>
<name><surname>Ono</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy</article-title><source>Jpn J Clin Oncol</source><year>2017</year><volume>47</volume><issue>9</issue><fpage>840</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">28633504</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aapro</surname><given-names>M</given-names></name>
<name><surname>Rugo</surname><given-names>H</given-names></name>
<name><surname>Rossi</surname><given-names>G</given-names></name>
<name><surname>Rizzi</surname><given-names>G</given-names></name>
<name><surname>Borroni</surname><given-names>ME</given-names></name>
<name><surname>Bondarenko</surname><given-names>I</given-names></name>
<etal>et al</etal>
</person-group><article-title>A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><issue>7</issue><fpage>1328</fpage><lpage>1333</lpage><pub-id pub-id-type="pmid">24603643</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hesketh</surname><given-names>PJ</given-names></name>
<name><surname>Bohlke</surname><given-names>K</given-names></name>
<name><surname>Lyman</surname><given-names>GH</given-names></name>
<name><surname>Basch</surname><given-names>E</given-names></name>
<name><surname>Chesney</surname><given-names>M</given-names></name>
<name><surname>Clark-Snow</surname><given-names>RA</given-names></name>
<name><surname>Danso</surname><given-names>MA</given-names></name>
<name><surname>Jordan</surname><given-names>K</given-names></name>
<name><surname>Somerfield</surname><given-names>MR</given-names></name>
<name><surname>Kris</surname><given-names>MG</given-names></name>
<collab>American Society of Clinical Oncology</collab>
</person-group><article-title>Antiemetics: American Society of Clinical Oncology Focused Guideline Update</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><issue>4</issue><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">26527784</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hesketh</surname><given-names>PJ</given-names></name>
<name><surname>Kris</surname><given-names>MG</given-names></name>
<name><surname>Basch</surname><given-names>E</given-names></name>
<name><surname>Bohlke</surname><given-names>K</given-names></name>
<name><surname>Barbour</surname><given-names>SY</given-names></name>
<name><surname>Clark-Snow</surname><given-names>RA</given-names></name>
<etal>et al</etal>
</person-group><article-title>Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>28</issue><fpage>3240</fpage><lpage>3261</lpage><pub-id pub-id-type="pmid">28759346</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>CC</given-names></name>
<name><surname>Hsing</surname><given-names>CH</given-names></name>
<name><surname>Shieh</surname><given-names>JP</given-names></name>
<name><surname>Chien</surname><given-names>CC</given-names></name>
<name><surname>Ho</surname><given-names>CM</given-names></name>
<name><surname>Wang</surname><given-names>JJ</given-names></name>
</person-group><article-title>The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting</article-title><source>Eur J Pharmacol</source><year>2014</year><volume>722</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">24184695</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Idzikowski</surname><given-names>C</given-names></name>
<name><surname>Shapiro</surname><given-names>CM</given-names></name>
</person-group><article-title>ABC of sleep disorders. Non-Psychotropic drugs and sleep</article-title><source>BMJ</source><year>1993</year><volume>306</volume><issue>6885</issue><fpage>1118</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">8495162</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarnes</surname><given-names>E</given-names></name>
<name><surname>Crofford</surname><given-names>L</given-names></name>
<name><surname>Watson</surname><given-names>M</given-names></name>
<name><surname>Dennis</surname><given-names>G</given-names></name>
<name><surname>Kan</surname><given-names>H</given-names></name>
<name><surname>Bass</surname><given-names>D</given-names></name>
</person-group><article-title>Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review</article-title><source>Clin Ther</source><year>2011</year><volume>33</volume><issue>10</issue><fpage>1413</fpage><lpage>1432</lpage><pub-id pub-id-type="pmid">21999885</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rundell</surname><given-names>JR</given-names></name>
<name><surname>Wise</surname><given-names>MG</given-names></name>
</person-group><article-title>Causes of organic mood disorder</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>1989</year><volume>1</volume><issue>4</issue><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">2521090</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodman</surname><given-names>RS</given-names></name>
<name><surname>Johnson</surname><given-names>DB</given-names></name>
<name><surname>Balko</surname><given-names>JM</given-names></name>
</person-group><article-title>Corticosteroids and Cancer Immunotherapy</article-title><source>Clin Cancer Res</source><year>2023</year><volume>29</volume><issue>14</issue><fpage>2580</fpage><lpage>2587</lpage><pub-id pub-id-type="pmid">36648402</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naeim</surname><given-names>A</given-names></name>
<name><surname>Dy</surname><given-names>SM</given-names></name>
<name><surname>Lorenz</surname><given-names>KA</given-names></name>
<name><surname>Sanati</surname><given-names>H</given-names></name>
<name><surname>Walling</surname><given-names>A</given-names></name>
<name><surname>Asch</surname><given-names>SM</given-names></name>
</person-group><article-title>Evidence-based recommendations for cancer nausea and vomiting</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>23</issue><fpage>3903</fpage><lpage>3910</lpage><pub-id pub-id-type="pmid">18688059</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meek</surname><given-names>R</given-names></name>
<name><surname>Graudins</surname><given-names>A</given-names></name>
</person-group><article-title>Visual analog scale rating change cut-offs for detection of improvement in nausea severity</article-title><source>Emerg Med Australas</source><year>2019</year><volume>31</volume><issue>4</issue><fpage>673</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">30950219</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Navari</surname><given-names>RM</given-names></name>
<name><surname>Pywell</surname><given-names>CM</given-names></name>
<name><surname>Le-Rademacher</surname><given-names>JG</given-names></name>
<name><surname>White</surname><given-names>P</given-names></name>
<name><surname>Dodge</surname><given-names>AB</given-names></name>
<name><surname>Albany</surname><given-names>C</given-names></name>
<etal>et al</etal>
</person-group><article-title>Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial</article-title><source>JAMA Oncol</source><year>2020</year><volume>6</volume><issue>6</issue><fpage>895</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">32379269</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noureddine</surname><given-names>LM</given-names></name>
<name><surname>Tr&#x000e9;dan</surname><given-names>O</given-names></name>
<name><surname>Hussein</surname><given-names>N</given-names></name>
<name><surname>Badran</surname><given-names>B</given-names></name>
<name><surname>Le Romancer</surname><given-names>M</given-names></name>
<name><surname>Poulard</surname><given-names>C</given-names></name>
</person-group><article-title>Glucocorticoid Receptor: A Multifaceted Actor in Breast Cancer</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>9</issue><size units="pages">4446</size></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vardy</surname><given-names>J</given-names></name>
<name><surname>Chiew</surname><given-names>KS</given-names></name>
<name><surname>Galica</surname><given-names>J</given-names></name>
<name><surname>Pond</surname><given-names>GR</given-names></name>
<name><surname>Tannock</surname><given-names>IF</given-names></name>
</person-group><article-title>Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><issue>7</issue><fpage>1011</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">16552437</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Celio</surname><given-names>L</given-names></name>
<name><surname>Cortinovis</surname><given-names>D</given-names></name>
<name><surname>Cogoni</surname><given-names>AA</given-names></name>
<name><surname>Cavanna</surname><given-names>L</given-names></name>
<name><surname>Martelli</surname><given-names>O</given-names></name>
<name><surname>Carnio</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study</article-title><source>Oncologist</source><year>2021</year><volume>26</volume><issue>10</issue><fpage>e1854</fpage><lpage>e1861</lpage><pub-id pub-id-type="pmid">34101934</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tienchaiananda</surname><given-names>P</given-names></name>
<name><surname>Nipondhkit</surname><given-names>W</given-names></name>
<name><surname>Maneenil</surname><given-names>K</given-names></name>
<name><surname>Sa-Nguansai</surname><given-names>S</given-names></name>
<name><surname>Payapwattanawong</surname><given-names>S</given-names></name>
<name><surname>Laohavinij</surname><given-names>S</given-names></name>
<etal>et al</etal>
</person-group><article-title>A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide</article-title><source>Ann Palliat Med</source><year>2019</year><volume>8</volume><issue>4</issue><fpage>372</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">31500422</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sutherland</surname><given-names>A</given-names></name>
<name><surname>Naessens</surname><given-names>K</given-names></name>
<name><surname>Plugge</surname><given-names>E</given-names></name>
<name><surname>Ware</surname><given-names>L</given-names></name>
<name><surname>Head</surname><given-names>K</given-names></name>
<name><surname>Burton</surname><given-names>MJ</given-names></name>
<etal>et al</etal>
</person-group><article-title>Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults</article-title><source>Cochrane Database Syst Rev</source><year>2018</year><volume>9</volume><issue>9</issue><size units="pages">CD012555</size><comment>Review</comment></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>M</given-names></name>
<name><surname>Baron</surname><given-names>I</given-names></name>
<name><surname>Beaulieu</surname><given-names>S</given-names></name>
<name><surname>Dufour</surname><given-names>A</given-names></name>
<name><surname>Letarte</surname><given-names>N</given-names></name>
<name><surname>Prady</surname><given-names>CC</given-names></name>
</person-group><article-title>Feasibility of olanzapine at reduced dose in highly emetogenic chemotherapy: a randomised controlled trial against aprepitant in triple therapy (FORESIGHT)</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>15</issue><supplement>suppl</supplement><size units="pages">12087</size></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bajpai</surname><given-names>J</given-names></name>
<name><surname>Kapu</surname><given-names>V</given-names></name>
<name><surname>Rath</surname><given-names>S</given-names></name>
<name><surname>Kumar</surname><given-names>S</given-names></name>
<name><surname>Sekar</surname><given-names>A</given-names></name>
<name><surname>Patil</surname><given-names>P</given-names></name>
<etal>et al</etal>
</person-group><article-title>Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial</article-title><source>Lancet Oncol</source><year>2024</year><volume>25</volume><issue>2</issue><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">38224701</pub-id>
</element-citation></ref></ref-list></back></article>